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Abstract 
BACKGROUND: The seroconversion is a significant health concern in patients with end-stage renal disease 
undergoing hemodialysis particularly in high endemic zones of HBV and HCV. 
PATIENTS AND METHODS: This prospective study was conducted from January 2009 to April 2018 at Sheri 
Kashmir Institute of Medical Sciences, Srinagar, Kashmir. A cohort of 459 end-stage renal disease patients on 
hemodialysis was enrolled from four dialysis centres and followed in a longitudinal manner. Their seroconversion 
rates, risk factors were studied. Positive patients were treated and followed up.  
RESULTS: This study demonstrated HBV seroconversion rate of 7.4 % (n = 34) and HCV seroconversion rate of 
10% (n = 46) in a cohort of 459 patients on hemodialysis attending four dialysis centres of Kashmir. Patients with 
diabetes mellitus outnumbered in seroconversion rates of (43.75%) followed by patients with glomerulonephritis 
(23.75%). Of 15 patients who had undergone renal transplantation 10 (66.67%), patients had seroconversion on 
hemodialysis which was statistically significant (P < 0.001). Patients who were dialysed at multiple HD centres 
had significant seroconversion than those who followed up at a single center. Seroconversion was associated with 
longer duration of dialysis (80.30 ± 30.92 vs 61 ± 9.41months, P < 0.000). HBV vaccination of the ESRD patient 
on hemodialysis was significantly protective against seroconversion (P = 0.000).  
CONCLUSIONS: Hepatitis B vaccination, stringent precautions in all dialysis centres could help to reduce the 
high seroconversion rates which have a high financial burden on ESRD patients. Intense health education to both 
patients and medical staff will be beneficial to lower the seroconversion rates. 
 
 
 
 
 
Introduction 
 
End-stage renal disease (ESRD) is an 
immune compromised state. Disturbed cell-mediated 
immunity is the hallmark of advanced renal failure. 
Studies have shown that patients on maintenance 
hemodialysis have lymphopenia and their T4 & T8 
lymphocyte are low. The uremic lymphocytes are 
shown to have lower proliferation rates compared to 
normal people and thus they become particularly 
susceptible to viral infections [1]. Over and above 
when on hemodialysis (HD) these patients are prone 
to contract various blood-borne infections like HBV, 
HCV, HIV etc. as HD requires access to the 
bloodstream and transmission can occur between 
patients and staff as well. Even ESRD patients 
receive multiple injections predisposing them to 
seroconversion.  
In a study by Moloughney et al., [2] authors 
concluded that an untreated percutaneous exposure 
to an infected source carries a risk of seroconversion 
of up to 30% for HBV. The risks for HCV and HIV 
even though lesser than HBV are estimated to be at 
1.8% and 0.31%, respectively after inadvertent 
percutaneous exposure. The seroconversion in ESRD 
patients on HD patients is particularly high. The 
Turkish multicentric trial has demonstrated the 
seroconversion rates to be higher among HD patients 
than on Continuous Ambulatory Peritoneal Dialysis 
(CAPD), authors advocated that CAPD compared to 
HD provided a potential advantage to the candidates 
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with the prospective renal transplant [3]. 
When patients with ESRD contract either HBV 
or HCV they invariably do not clear the virus and 
progress to chronic hepatitis. A meta-analysis of 
clinical studies based on 145,608 patients, anti-HCV 
seropositive status was a significant risk factor for 
death in patients on long-term dialysis [4]. Authors in 
the study mentioned above showed that ESRD 
patients with HCV positivity on dialysis are prone to 
have a higher cardiovascular risk making treatment of 
chronic HCV imperative among these patients.  
Even though the treatment of HBV and HCV 
have become safer, better tolerated and more 
effective owing to the availability of direct-acting anti-
virals for nearly all patients the cost factors continue to 
be high. Added to this chronic HBV and chronic HCV 
patients need regular follow up to assess the 
development of complications like decompensation 
and hepatocellular carcinoma. In a Canadian study, 
chronic HCV was shown to be highly burdensome to 
public health causing loss of productive years of life 
than any other infectious disease in that country [5]. 
Keeping in view a high prevalence of HBV and HCV in 
our region we were prompted to undertake this study, 
first of its kind, among hemodialysis patients. We 
estimated HBV and HCV seroconversion rates in 
patients undergoing maintenance HD at four dialysis 
centres as invariably maintenance hemodialysis is not 
being carried out at our tertiary care centre keeping in 
view limited resources and increased demand.  
 
 
Patients and Methods  
 
This study was carried out prospectively from 
January 2009 to April 2018. The enrolled patients 
gave written consent for the participation in the study 
and various laboratory tests were carried out at a 
bimonthly interval in each participant. The data were 
maintained on our dialysis register. Our study was 
conducted in full compliance with the guidelines for 
good clinical practice of the World Medical Assembly 
Declaration of Helsinki and the research guidelines of 
the Sheri Kashmir Institute of Medical science 
(SKIMS) Srinagar Kashmir, a tertiary care centre in 
the valley of Kashmir.  
 
Study Population  
From January 2009 to April 2018, 470, 
patients on hemodialysis were enrolled. Socio-
demographic data were collected. These data 
included age, gender, duration of hemodialysis 
treatment, the frequency of dialysis, history of 
diabetes, blood transfusions, renal transplantation, 
surgical interventions and possible household 
acquirement of hepatitis infection. The medical 
records of the study participants were tabulated at the 
beginning regularly updated on follow up. 
 
Definition of HBV and HCV Status  
All patients had a baseline hemogram, liver 
function tests and HBsAg and anti HCV samples 
collected at the enrolment into the study. Then at a 
bimonthly interval, HBsAg detection was done by 
immunoassay and viral DNA (HBV DNA) Quantitative 
was estimated by real-time PCR (Roche Cobas 
Ampliprep) in HBV positive patients. Third generation 
ELISA test was used to detect anti HCV, and Hepatitis 
C viral RNA Quantitative was estimated by real-time 
PCR (Cobas TaqMan) in HCV positive patients. 
The seroconversion was defined as a change 
from HCV antibody negative at the time of enrollment 
to HCV antibody positive status during the study 
period with high HCV RNA. 
 
Exclusion criteria 
1. Patients known to be positive for HBV and 
HCV at the time of enrollment were excluded.  
2. Patients who had received a blood 
transfusion in the last three months at the time of 
enrolment.  
3. Clinical Jaundice or high AST/ALT levels at 
the time of enrolment due to any reason.  
  
Statistical Analysis 
All the data were entered into Microsoft Excel. 
This included demographic profiles of participants, the 
cause of end-stage renal disease etc. We compared 
the two groups HCV and HBV positive with hepatitis 
negative patients. The analysis was focused on 
seroconversion, risk factors contributing to 
seroconversion during hemodialysis. Descriptive and 
analytical, methods were used throughout data 
analysis using SPSS version 21.  
Data are presented as mean ± standard 
deviation or number (percentages). Chi-square test 
and Fisher’s exact test were used, when appropriate. 
P ≤ 0.05 was considered as statistically significant. 
Odds ratios (OR) were calculated considering the 
confidence interval of 95%.  
 
 
Results  
 
A total of 470 patients were enrolled during 
the study period. Eleven patients lost to follow up, and 
finally data on 459 patients on hemodialysis were 
evaluated. Of 459 participating subjects, the majority 
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275 (60%) were males. Mean age ± SD in the sero 
converted group was 63.09 ± 7.99 and age ranged 
42-72 years. While the mean age in seronegative 
patients was 61.78 ± 9.411 and their age ranged 39-
72 years. The duration of dialysis was 80.30 ± 30.92 
(10-142 months) in sero converted patients and 61 ± 
9.41(39-72) months in seronegative patients. The 
difference was statistically significant (p = 0.000) as 
shown in Table 1. Seroconversion was significantly 
higher in patients who had dialysis at multiple centres 
as shown in Table 1. Significant association of 
seroconversion was observed in patients with a renal 
transplant. Vaccination status was significantly 
protective in the prevention of seroconversion of viral 
hepatitis B (p = 0.00). 
Table 1: Clinical data of seroconverted and seronegative 
patients on HD 
Factors associated with seroconversion  Sero Positive 
N = 80 
Sero negative 
N = 379 
P value 
Age in years (mean ± SD) 63.09 ± 7.99 61.78 ± 9.411 0.407 
Males (No & %) 48 (60%) 242 (63.85%) 0.998 
Mean duration of Dialysis in months  80.3 0± 30.92 61 ± 9.41 0.000 
Previous blood transfusion 
a. No blood transfusion  
b. Less than 2 units  
c. Three or > 3 units  
 
17 (21.5%) 
56 (70.9%) 
6 (7.6%) 
 
96 (25.3%) 
245 (64.6%) 
38 (10%) 
 
 
0.556 
Previous renal transplant (Median & IQR) 10 (73.34%) 5 (14.7%) 0.034 
Erythropoietin treatment % 55 (69.65%) 266 (70.2%) 0.920 
Visit to Multiple HD centers  75 (94.9%) 173 (45.6%) 0.00 
HBV vaccination status  
a. Fully vaccinated  
b. Partially vaccinated  
c. Not vaccinated 
 
6 (7.6%) 
35 (44.3%) 
39 (48.1%) 
 
185 (48.8%) 
174 (45.9%) 
20 (5.3%) 
 
 
0.000 
 
The study cohort had low haemoglobin levels, 
and there was no statistical difference between 
seroconverted or negative patients. The renal 
functions also showed no significant difference 
between the two groups. While AST and ALT levels 
were low in both groups but there was a significant 
difference between seroconverted and negative 
groups. Serum uric acid levels were significantly 
elevated in the seroconverted group compared to 
negative groups. There was no difference in the 
serum Albumin levels between the two groups Table 
2. 
Table 2: Laboratory data Investigations in the Cohort of ESRD 
on Hemodialysis 
Investigation  HBV + ve HCV + ve Seronegative group P valve 
 
Hemoglobin (median (IQR)) 8.5 (1.6) 8.6 (1.5) 8.5 (1.5) 0.575 
Platelet (median (IQR)) 180 (19) 188 (20) 180 (20) 0.361 
WBC (median (IQR)) 4.9 (0.62) 4.76 (0.74) 4.73 (1.0) 0.256 
Urea (median (IQR)) 182 (20) 180 (21) 187 (25) 0.166 
Creatinine (median (IQR)) 9.0 (2.4) 9.2 (2.1) 9.5 (1.0) 0.745 
Uric acid  6.7 (0.5) 6.7 (0.5) 6.5 (1.0) 0.008 
Calcium  9.8 (1.2) 9.4 (0.65) 9.5 (1.0) 0.098 
Phosphorus  4.1 (0.4) 4.1 (0.4) 4.1 (0.4) 0.773 
Bilirubin (mg/dl) 0.8 (0.5) 0.8 (0.4) 0.8 (0.3) 0.867 
ALT IU 22 (8) 22 (8) 18 (0.5) 0.000 
AST IU 23 (7) 22 (6) 18 (2) 0.000 
ALP(KA) 80 (1.1) 80 (1.1) 80 (2.7) 0.403 
T. Protein (g/dl) 7.6 (1) 7.7 (1.3) 7.6 (1.2) 0.888 
Albumin (g/dl) 4.7 (.7) 4.7 (.7) 4.7 (.7) 0.942 
 
Primary objective: Seroconversion of 
Hepatitis B and Hepatitis C 
Of 459 patients on hemodialysis, 80 (17.42%) 
patients had seroconversion. HBV seroconversion 
was observed among 34 (7.4%) patients and HCV in 
46 (10.2%) patients. The mean interval was 6 ± 1.2 
months and ranged from 4 months to 11 months in 
our study. None of our study cohorts had HBV and 
HCV combined infection. Depending upon the cause 
of ESRD seroconversion rates varied as under as 
shown in shown in Figure 1. 
 
Figure 1: Seroconversion rates as per the aetiology of ESRD 
patients on HD 
 
1. Diabetes mellitus: Diabetes mellitus was 
the most common cause of ESRD in this study. Of 
213 diabetic patients on hemodialysis seroconversion 
was observed in 35 (16.43%) patients [HBV=16, 
HCV=19] corresponding to 35/80 (43.75%) of all 
seroconverted patients in our study cohort as shown 
in Figure 1. 
2. Chronic glomerulonephritis: Of 108 patients 
with chronic glomerulopathies on hemodialysis 
seroconversion was found in 19 (17.59%) patients 
[HBV = 8, HCV = 11] corresponding to 19/80 (23.75%) 
as shown in Figure 1. 
3. Hypertension: Of 62 patients with chronic 
hypertension on hemodialysis seroconversion was 
found in 10 (22.58%) patients [HBV = 4, HCV = 6] 
corresponding to 10/80 (12.5%) of our study cohort. 
4. Post-Transplant: There were 15 patients 
post-transplant on hemodialysis in this study. Various 
reasons ascribed to their transplant failure were, 
chronic rejection 8 (53.34%) BK Virus 4 (26.67%) 
antibody rejection 3 (20%). Of 15 post renal transplant 
patients, seroconversion was observed in 10 (66.67%) 
patients [HBV = 5, HCV = 5], corresponding to 10/80 
(12.5%) of our study cohort. 
5. Adult polycystic kidney disease ADPKD: 
There were 22 patients with ADPKD on hemodialysis. 
The seroconversion was in 3 (13.63%) patients [HBV 
= 1, HCV = 2], 3/80 (3.75%) of our study cohort as 
shown in Figure 1. 
6. Obstructive Uropathy: There were 7 
patients with obstructive uropathy, and none of them 
underwent seroconversion. 
7. Chronic interstitial nephritis CIN: Of 12 
patients with CIN no patient underwent 
seroconversion.  
8. Unknown cause of ESRD: Of 17 patients 
where the cause of ESRD remained unknown 
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seroconversion was observed in 3 (17.64%) patients 
[HBV = 0, HCV = 3] corresponding to 3/80 (3.75%) of 
our study cohort as shown in Figure 1.  
 
Treatment of HCV, HBV and follow up: 
All patients with HBV were treated with Tab. 
Entecavir 0.5mg once every 5 days. There was a 
progressive fall in HBV DNA levels in all patients. 
Patients with HCV were initially treated with 
Interferon-based therapy at the start of the study and 
later with oral drugs when oral drugs became 
available. Both HBV and HCV seroconverted patients 
were followed by ultrasound liver examination every 
six month, and AFP levels were monitored. There was 
no evidence of HCC in any of the study participants 
during the study period.  
 
 
Discussion 
 
This study demonstrated an HBV 
seroconversion rate of 7.2% and HCV seroconversion 
rate of 10% in a cohort of 459 ESRD patients on 
maintenance hemodialysis (HD). The mean time from 
the start of HD to seroconversion was 6 ± 1.2 months, 
and it ranged from 6 months to 11 months. As 
summarized in Table 3 the prevalence of HBV and 
HCV in various HD units varies from country to 
country across the globe and the prevalence in the 
Indian HD centers continues to be high [6], [7], [8], [9], 
[10], [11], [12], [13], [14], [15], [16], [17]. 
Table 3: Global data of seroprevalence of HBV & HCV in HD 
centres 
Virus Place Author Year Prevalence 
 
 
HBV 
Western Europe Japan 
&USA  
Burdick et al [6]
 
2003 0-6.6% 
Middle East: 
Saudi Arabia & Bahrain 
Almawi WY et al [7] 2004 11.8% & 3.7% 
Turkey Yakaryilmaz et al [8]
 
2006 13.3% 
Brazil Ferreira et al [9]
 
2006 2.4-10% 
Asia & Pacific countries  Johnson et al [10]
 
2009 1.3% & 14.6% 
North Indian data  Malhotra R et al [11]
 
2016 1.5-33.5% 
 
 
HCV 
United Kingdom Wreghitt et al. [12]. 1999 4% 
Saudi Arabia  Souqiyyeh et al [13]
 
2001 50% 
Germany Hinrichsen H et al [14]
 
2002 6% 
Slovenia  Buturovic-Ponikvar et al [15] 2003 1.9% 
Casablanca Boulaajaj K et al [16]
 
2005 76% 
Egypt  ZahranAM [17] 2014 49.6% 
 
The risk of seroconversion in ESRD on HD is 
directly proportional to the prevalence of viral infection 
in a given society and the quality of dialysis centres. In 
this study, as shown in Figure 1 the patients with 
Diabetes mellitus had higher seroconversion rates 
than the non-diabetic population which has been 
demonstrated by other researchers as well [18], [19]. 
The seroconversion was proportional to duration of 
dialysis in years possibly due to increased nosocomial 
infection rates in HD population as demonstrated by 
Carneiro et al., [20]. Patients who were dialysed at 
multiple dialysis centres had more seropositivity rates 
compared to those who followed in a single centre as 
shown in Table 1 supported by Petrosillo et al., [21]. 
There was no marked elevation of AST and 
ALT levels in the seroconverted group. Nevertheless 
the difference between seroconverted and negative 
patients on HD was statistically significant (Table 2). 
Patients with the end-stage renal disease do not show 
a marked rise of AST and ALT levels following 
seroconversion warranting a high clinical suspicion as 
the actual liver damage may be profound irrespective 
of AST levels. As such, it has been suggested by 
Wong et al., [22] that in a dialysis patient with chronic 
HBV infection an unexplained elevation in serum ALT 
level persistently above 30 IU/L or just 0.75 times 
upper limit of normal (ULN), liver biopsy should be 
considered to rule out significant hepatic inflammation 
if the clinical evidence of progressive liver disease is 
high. 
Our study demonstrated a significant 
elevation of serum uric acid (UA) levels in the 
seroconverted group compared to the seronegative 
group as shown in Table 1. In a study by Afzali A et 
al., [23] the data on 5518 participants during a mean 
follow of 12 years showed that the high serum uric 
acid levels strongly predicted the progression of liver 
disease. In their study serum UA level was associated 
with the development of cirrhosis. There was no 
significant association observed in hemogram, serum 
calcium, phosphorous, serum proteins, albumin levels 
between the two groups as shown in Table 2. 
Prevention seems to be the cornerstone in 
declining seroconversion rates of HBV and HCV in HD 
patients. As per the guidelines of CDC endorsed by 
Kidney Disease: Improving Global Outcomes (KDIGO) 
[24], stringent precautions in dialysis units must be 
observed to decline seroconversion rates. These 
include wearing and changing of gloves after a clinical 
encounter with HD patient, isolation of positive 
patients, water-proof gowns between patients, 
systematic decontamination of the equipment circuit 
and surfaces after each patient’s treatment. CDC also 
refrains sharing of various instruments like 
tourniquets, stethoscope, blood pressure cuff and use 
of multi-use vials of heparin between HD patients [25]. 
Apart from stringent precautions the use of 
recombinant erythropoietin (EPO) therapy seems to 
be the plausible solution in preventing the 
seroconversion among HD patients. However, blood 
transfusions cannot be avoided entirely in end-stage 
renal disease (ESRD). There are situations when 
ESRD patients need to be transfused exposing them 
to the risk of seroconversion especially when they 
develop EPO resistance due to suboptimal dialysis 
[26]. However, blood transfusion rates didn’t affect 
sero positivity in our study as shown in Table 1.  
The occult HBV remains another potential risk 
of seroconversion and its prevalence as demonstrated 
by Gutiérrez-García et al., [27] is parallel with the 
prevalence of apparent HBV infection prevalence. 
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This poses a significant risk of seroconversion not 
only during transfusion but also during the disease 
among ESRD patients on HD. Various studies have 
shown that the prevalence of occult hepatitis B in 
dialysis patients ranges between 0% and 58% [28], 
[29]. Thus whether the higher seroconversion rates 
observed in this study were due to activation of occult 
hepatitis B or due to some other reasons remained 
elusive. The enigma could have been solved had we 
checked HBV DNA in all patients undergoing 
hemodialysis but due to financial constraints, such 
practice may not be feasible everywhere. Having said 
this, keeping in view a high prevalence of HBV in our 
region whether testing for Anti-HBc antibody & HBV 
DNA levels both in a given blood donor and the ESRD 
patient before enrolment to hemodialysis will help to 
reduce further transmission needs to be studied. This 
has particular public health importance in our region 
as the number of dialysis units is limited, and the 
ESRD patient population on HD is on rise due to the 
shortage of renal transplantation facilities. 
With the advent of Hepatitis B vaccination 
there has been a progressive decline in new 
conversion rates all over the globe. There was a 
significant association between vaccination status and 
seroconversion as shown in Table 1. Since there is no 
vaccine against HCV, aseptic precautions in various 
dialysis centres can decline the incidence of HCV 
seroconversion. Way back in 1977 when CDC 
guidelines [30] were laid Dinits-Pensy et al., [31] 
demonstrated a decline of new HBV among HD 
patients from 6.2 to 1% among US dialysis centres a 
few years later.  
In another study, the prevalence of HBV 
infection in HD patients in the United States of 
America progressively fell from 7.8% to 1.0% between 
1976 and 2002. Similarly, the prevalence of HCV 
infection fell from 10.4% to 7.8% from 1995 to 2002 
[32]. Hemodialysis environment proves to be the 
vehicles of transmission of these viruses and renal 
transplant seems to be another modality in 
circumventing this vicious cycle. The Iranian data 
showed a significant fall of seroconversion after renal 
transplantation in ESRD patients [33]. 
There was a higher HCV seroconversion 
(10%) than HBV seroconversion rates (7.2%) possibly 
due to a higher prevalence of HCV in our region as 
demonstrated by Jasuja et al., [34]. We utilized 
utilised the third generation of enzyme-linked 
immunosorbent assay (ELISA) for the detection of anti 
HCV. Various studies have shown that the frequency 
of HCV RNA-positive among anti-HCV-negative 
patients undergoing HD varies from 0% to 12% [35], 
[36]. Nevertheless, routine screening of HCV RNA in 
our patient population with limited resources and no 
insurance coverage may not be feasible and 
serological testing, preferably by the third-generation 
enzyme-linked immunosorbent assay (ELISA) has 
been recommended for routine screening of HD 
patients [37]. Recently occult HCV has been 
demonstrated in the liver tissue and peripheral blood 
mononuclear cells of HCV RNA negative patients on 
HD connoting that despite negative HCV RNA and 
serology patients can have HCV infection and 
potentially transfer via dialysis units or get activated in 
the given patient [38]. 
The high percentage of seroconversion in this 
study could be partly attributed to the shortage of 
nursing staff, in an environment of a high prevalence 
of HBV and HCV positivity in our region. Further, 
invariably our HD units remain crowded units due to 
limited resources. Last but not least there are 
inadequate infection control policies and procedures 
in this part of the globe. 
The drawback of our study, we believe, is that 
we did not calculate fibrosis scores in our cohort of 
seroconverted patients. However, all patients were 
Child Turcot Pugh class A and no patient had 
decompensation on follow up. The seroconverted 
patients were treated and regularly followed with Alfa-
fetoprotein (AFP) levels and six-monthly ultrasound of 
the liver. None of our study participants developed 
Hepatocellular carcinoma during the study period. In a 
study by Cheng et al., [39], while comparing the 
outcome of hepatic resection in patients with CRF and 
normal kidney functions tests, it was observed that 
even though ESRD patients had high creatinine levels 
and low haemoglobin, a similar outcome in both 
ESRD & controls groups was observed by the 
authors. Their study highlights that patients with 
seroconversion must be followed up for HCC and 
operated as per the standard protocol. 
We conclude that a high prevalence of viral 
hepatitis seroconversion among ESRD patients on 
hemodialysis was observed. All our efforts must be to 
prevent seroconversion of ESRD patients on HD by 
adequate HBV vaccination (40 µg HBV vaccine at 0, 
1, 2 and six months) and unpermissive precautions in 
hemodialysis centres. Nevertheless, after an 
unfortunate seroconversion, ESRD patients must be 
treated with standard therapy which is safe and 
effective.  
Our study emphasises enforcement of the 
quality control in various dialysis centres by 
healthcare authorities across the state, including 
periodic serological testing of dialysis staff. The 
practice guidelines must be laid, and rigorous infection 
control policies must be adopted by all the dialysis 
centres in the region to prevent the longterm 
consequences of seroconversion among ESRD 
patients on hemodialysis. 
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